HTG Molecular Diagnostics, Inc.

符号: HTGM

NASDAQ

0.48

USD

今天的市场价格

-0.0745
市盈率
-0.0008
PEG比率
1.06M
MRK市值
0.00%
DIV收益率

HTG Molecular Diagnostics, Inc. (HTGM) 财务报表

Q: 什么是 HTG Molecular Diagnostics, Inc. (HTGM) 总资产是多少？

HTG Molecular Diagnostics, Inc. (HTGM) 总资产为 .

Download

年度季度

线性对数

在图表中，您可以看到的动态默认数字 HTG Molecular Diagnostics, Inc. (HTGM). 的默认数据。公司收入显示 NaN M 的平均值，即 NaN % 增长率。整个期间的平均毛利润为 NaN M，即 NaN %. 平均毛利率为 NaN %. 公司去年的净收入增长率为 NaN %，等于 NaN % % 整个公司历史的平均增长率.,

年度季度

10Y 20Y 30Y 40Y

资产负债表

深入分析 HTG Molecular Diagnostics, Inc. 的财务轨迹，我们可以看到其平均资产增长率。有趣的是，这一增长率为，反映了公司的高点和低点。与季度相比，这一数字调整为. 回顾过去一年，总资产变化为 NaN. 股东权益总额所体现的股东价值是以报告货币计算的 NaN. 这方面的年同比变化率为 NaN%.

common:word.in-mln USD Growth	TTM	2021	2019	2017	2015	2013
balance-sheet.row.cash-and-short-term-investments	39.4	12.2	21.9	28.7	33	31.1	10	11.8	31.5	3.6	1.8	7.3
balance-sheet.row.short-term-investments	15.23	0	12.3	6.3	25.4	22.7	0	4.3	28.2	0	0	0
balance-sheet.row.net-receivables	4.77	1.4	2.1	1.6	3.2	5	6.4	1.4	0.7	0.8	0.6	0.2
balance-sheet.row.inventory	5.21	0.9	2	1.5	1.3	1.3	1.2	1.5	2.2	1.5	0.7	0.1
balance-sheet.row.other-current-assets	4.89	1.1	1.2	1.1	0.6	0.6	0.4	0.4	0.4	0.1	0.2	0.2
balance-sheet.row.total-current-assets	54.94	15.7	27.2	32.9	41.4	38	17.9	15.1	34.9	6	3.3	7.8
balance-sheet.row.property-plant-equipment-net	6.65	1.6	2.5	2.2	3.4	2.4	3.3	3.3	1.9	1.4	1.1	0.6
balance-sheet.row.goodwill	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.intangible-assets	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.goodwill-and-intangible-assets	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.long-term-investments	0	0	0	0	0	0	0	0	2.6	0	0	0
balance-sheet.row.tax-assets	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.other-non-current-assets	2.88	0.5	0.8	0.1	0.3	3.4	0	0	0.1	1.4	0	0
balance-sheet.row.total-non-current-assets	9.52	2.1	3.3	2.3	3.8	5.8	3.3	3.3	4.6	2.7	1.1	0.6
balance-sheet.row.other-assets	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-assets	64.46	17.8	30.5	35.2	45.1	43.8	21.3	18.5	39.4	8.7	4.4	8.4
balance-sheet.row.account-payables	4.08	1.2	1.6	1.3	1.7	1.8	2.4	0.8	0.7	0.9	0.8	0.6
balance-sheet.row.short-term-debt	19.02	4.3	5.6	3.7	3.7	0	5.8	6.4	3.1	0.8	0	0
balance-sheet.row.tax-payables	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.long-term-debt-total	4.92	0.5	6.1	8.9	7.5	9.7	3	5.4	7.8	10.4	0	0.2
Deferred Revenue Non Current	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.deferred-tax-liabilities-non-current	0	-	-	-	-	-	-	-	-	-	-	-
balance-sheet.row.other-current-liab	8.71	2.8	2.6	2	3.1	4.8	4.4	2.5	2.5	1.5	1.5	1.1
balance-sheet.row.total-non-current-liabilities	20.01	4.1	10.1	13.5	12.3	15.7	11	14	16.2	29.5	24.5	24.9
balance-sheet.row.other-liabilities	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.capital-lease-obligations	3.41	1	1.4	1.1	1.4	0	0	0	0	0	0	0
balance-sheet.row.total-liab	51.81	12.4	20.1	20.7	21.1	22.7	24.3	24	22.6	32.8	26.8	26.7
balance-sheet.row.preferred-stock	0	0	0	0	0	0	0	0	0	45.6	35.8	25.9
balance-sheet.row.common-stock	0.03	0	0	0	0.1	0	0	0	0	0	0	0
balance-sheet.row.retained-earnings	-910.86	-229.9	-208.3	-191.2	-170.3	-151	-134.6	-115.6	-89.6	-68.2	-54.2	-42.4
balance-sheet.row.accumulated-other-comprehensive-income-loss	-0.02	0	0	0	0	0	0	0	0	-2	-1.5	-1.2
balance-sheet.row.other-total-stockholders-equity	923.5	235.3	218.7	205.7	194.2	172.1	131.5	110	106.5	0.5	-2.6	-0.6
balance-sheet.row.total-stockholders-equity	12.64	5.4	10.4	14.5	24	21.1	-3.1	-5.6	16.9	-24	-22.4	-18.3
balance-sheet.row.total-liabilities-and-stockholders-equity	64.46	17.8	30.5	35.2	45.1	43.8	21.3	18.5	39.4	8.7	4.4	8.4
balance-sheet.row.minority-interest	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-equity	12.64	5.4	10.4	14.5	24	21.1	-	-	-	-	-	-
balance-sheet.row.total-liabilities-and-total-equity	64.46	-	-	-	-	-	-	-	-	-	-	-
Total Investments	15.23	0	12.3	6.3	25.4	22.7	0	4.3	30.8	0	0	0
balance-sheet.row.total-debt	23.94	4.8	11.7	12.6	11.3	32.4	8.8	11.8	10.8	11.2	0	0.2
balance-sheet.row.net-debt	-0.24	-7.4	2.1	-9.8	3.6	23.9	-1.2	4.3	7.6	7.6	-1.8	-7.1

现金流量表

在 HTG Molecular Diagnostics, Inc. 的财务状况中，自由现金流在过去一段时间内发生了显著变化，呈现出 NaN 的转变。该公司最近通过发行 NaN 扩大了股本，与上一年相比出现了NaN 的差异. 公司的投资活动产生了现金使用净额，按报告货币计算达到NaN. 与上一年相比， NaN 发生了变化. 在同一时期，公司记录了 NaN, NaN 和 NaN，这对于了解公司的投资和还款策略具有重要意义. 公司的融资活动导致使用的现金净额为NaN，同比差异为NaN. 此外，公司还将NaN 用于向股东分红。与此同时，该公司还采取了其他财务措施，即 NaN，这也对其在此期间的现金流产生了重大影响. 这些组成部分合在一起，全面反映了公司的财务状况和现金流管理的战略方针。

common:word.in-mln USD Growth	TTM	2021	2019	2017	2015	2013
cash-flows.row.net-income	-20.15	-21.6	-17.1	-20.9	-19.3	-16.5	-19	-26	-21.4	-14	-11.8	-12.8
cash-flows.row.depreciation-and-amortization	0.49	0.6	0.7	1.3	1.7	1.5	1.2	1.5	0.7	0.5	0.3	0.2
cash-flows.row.deferred-income-tax	0	0	-1.4	0.7	0.2	0	0	0	0	0	0	0
cash-flows.row.stock-based-compensation	0.68	0.8	1.4	1.8	1.2	1.9	1.4	1	0.4	0.2	0.1	0.1
cash-flows.row.change-in-working-capital	-0.16	-0.1	-1	-0.2	-0.5	0	-1.2	-0.3	-0.9	-0.7	-0.5	1.3
cash-flows.row.account-receivables	-0.38	0.7	-0.8	1.6	1.8	1.3	-5	-0.7	0	-0.3	-0.5	1.7
cash-flows.row.inventory	0.27	0.1	-1.4	-0.3	-0.1	-0.2	0.1	0	-0.7	-0.7	-0.6	-0.1
cash-flows.row.account-payables	-0.2	-0.5	0.5	0	-0.2	-0.2	1.2	0	-0.3	0.2	0.1	0
cash-flows.row.other-working-capital	0.16	-0.4	0.7	-1.5	-2.1	-1	2.5	0.4	0.1	0.2	0.4	-0.3
cash-flows.row.other-non-cash-items	2.31	1.9	0.9	0.9	0	-0.2	0.9	1.6	2	0.9	0.1	2.5
cash-flows.row.net-cash-provided-by-operating-activities	-16.83	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.investments-in-property-plant-an-equipment	-0.02	0	-0.6	-0.5	-1.1	-0.9	-1	-1.9	-1.3	-0.9	-0.8	-0.1
cash-flows.row.acquisitions-net	-99828.51	0	-25018	-72.5	-325666	-412436	0	172	0	0	0	0
cash-flows.row.purchases-of-investments	-11.15	-7.6	-18.6	-12.5	-34.6	-54	0	-3.4	-38.3	0	0	0
cash-flows.row.sales-maturities-of-investments	14.52	19.9	12.6	31.6	32.2	31.7	4.3	29.8	7.5	0	0	0
cash-flows.row.other-investing-activites	99828.64	0.1	25018	72.5	325666	412436	0	-172	0	0	0	0
cash-flows.row.net-cash-used-for-investing-activites	3.48	12.4	-6.7	18.7	-3.5	-23.2	3.3	24.4	-32.2	-0.9	-0.8	-0.1
cash-flows.row.debt-repayment	-7.16	-7.8	-0.8	-3.6	0	-6	-6.5	-4.6	0	-0.8	0	0
cash-flows.row.common-stock-issued	2.8	1.4	10.7	7.5	20.8	38.3	20.2	2	47.7	0	0	0
cash-flows.row.common-stock-repurchased	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.dividends-paid	0	0	0	0	0	0	0	0	-1165.9	0	0	0
cash-flows.row.other-financing-activites	6.09	15	0.5	5.1	-1.3	5.9	2	4.6	1169.4	16.4	7.1	7.2
cash-flows.row.net-cash-used-provided-by-financing-activities	1.73	8.6	10.4	9	19.4	38.1	15.8	2	51.1	15.7	7.1	7.2
cash-flows.row.effect-of-forex-changes-on-cash	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.net-change-in-cash	-11.62	2.6	-12.8	11.5	-0.8	1.7	2.5	4.2	-0.3	1.8	-5.5	-1.6
cash-flows.row.cash-at-end-of-period	24.18	12.2	9.6	22.4	10.9	11.7	10	7.5	3.3	3.6	1.8	7.3
cash-flows.row.cash-at-beginning-of-period	35.79	9.6	22.4	10.9	11.7	10	7.5	3.3	3.6	1.8	7.3	8.9
cash-flows.row.operating-cash-flow	-16.83	-18.4	-16.5	-16.3	-16.7	-13.2	-16.6	-22.2	-19.2	-13	-11.8	-8.7
cash-flows.row.capital-expenditure	-0.02	0	-0.6	-0.5	-1.1	-0.9	-1	-1.9	-1.3	-0.9	-0.8	-0.1
cash-flows.row.free-cash-flow	-16.85	-18.4	-17.2	-16.7	-17.8	-14.1	-17.6	-24.2	-20.6	-13.9	-12.6	-8.7

利润表行

HTG Molecular Diagnostics, Inc. 的收入与上期相比变化了 NaN%。据报告, HTGM 的毛利润为 NaN。该公司的营业费用为 NaN，与上年相比变化了 NaN%. 折旧和摊销费用为 NaN，与上一会计期间相比变化了 NaN%. 营业费用报告为 NaN，显示NaN% 的同比变化。销售和营销费用为 NaN, 其中 NaN% 与上年相比发生了变化。基于近期数据的EBITDA为 NaN，同比增长NaN%. 营业收入为 NaN，与上年相比变化了NaN%. 净利润的变化率为 NaN%。去年的净收入为NaN.

common:word.in-mln USD Growth	TTM	2021	2019	2017	2015	2013
income-statement-row.row.total-revenue	6.21	6.4	8.9	8.5	19.2	21.5	14.8	5.1	4	3.3	2.2	2.5
income-statement-row.row.cost-of-revenue	4.87	4.6	4.1	4	8.9	5.1	5	4.1	3.3	3.2	2.2	1.8
income-statement-row.row.gross-profit	1.35	1.8	4.8	4.6	10.3	16.4	9.8	1	0.7	0.1	0	0.7
income-statement-row.row.gross-profit-ratio	0	0	0	0	0	0	0	0	0	0	0	0
income-statement-row.row.research-development	6.47	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.selling-general-administrative	0	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.selling-and-marketing-expenses	0	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.other-expenses	-0.24	0	-1	0	0	0	0	0	0	9.9	7.7	7.3
income-statement-row.row.operating-expenses	20.94	22.6	22.6	24.1	29.3	32.6	27.5	25.3	19.6	13	11.9	11.2
income-statement-row.row.cost-and-expenses	25.8	27.2	26.7	28.1	38.2	37.7	32.5	29.5	22.9	16.2	14.2	13
income-statement-row.row.interest-income	0.19	0.1	0	0.3	0.6	0.7	0.1	0.1	0.1	0	0	0
income-statement-row.row.interest-expense	0.75	0.9	1.1	1	1	0.9	1.3	1.9	1.7	0.7	0.2	0.3
income-statement-row.row.selling-and-marketing-expenses	0	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.total-other-income-expensenet	-0.55	-0.8	0.7	-1.3	-0.3	-0.3	-1.2	-1.7	-2.5	-1.1	0.1	-2.2
income-statement-row.row.ebitda-ratio-caps	0	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.other-operating-expenses	-0.24	0	-1	0	0	0	0	0	0	9.9	7.7	7.3
income-statement-row.row.total-operating-expenses	-0.55	-0.8	0.7	-1.3	-0.3	-0.3	-1.2	-1.7	-2.5	-1.1	0.1	-2.2
income-statement-row.row.interest-expense	0.75	0.9	1.1	1	1	0.9	1.3	1.9	1.7	0.7	0.2	0.3
income-statement-row.row.depreciation-and-amortization	0.55	0.7	-1.7	1.6	2.4	1.5	1.2	1.5	0.7	0.5	0.3	0.2
income-statement-row.row.ebitda-caps	-19.29	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.operating-income	-19.59	-20.8	-17.8	-19.6	-19	-16.2	-17.7	-24.3	-18.9	-12.8	-11.9	-10.5
income-statement-row.row.income-before-tax	-20.14	-21.6	-17.1	-20.9	-19.3	-16.5	-19	-26	-21.4	-14	-11.8	-12.8
income-statement-row.row.income-tax-expense	0.01	0	0	0	0	0	0	0	0	-0.4	0.4	-2
income-statement-row.row.net-income	-20.15	-21.6	-17.1	-20.9	-19.3	-16.5	-19	-26	-21.4	-14	-11.8	-12.8